Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: A new mechanism of action

Journal of Molecular and Cellular Cardiology

Volumn 36, Issue 3, 2004, Pages 445-453

  Yu, Cheuk Man ^a   Wing Hon Lai, Kevin ^b   Li, Pik Shan ^b   Lam, Kar Yee ^b   Leung, Joseph C K ^b   Lai, Kar Neng ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 1; AQUAPORIN 2; FOSINOPRIL; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HEART INFARCTION; KIDNEY CORTEX; KIDNEY MEDULLA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSCRIPTION REGULATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUAPORIN 2; AQUAPORINS; DRUG THERAPY, COMBINATION; FOSINOPRIL; GENE EXPRESSION; HEART FAILURE, CONGESTIVE; KIDNEY CORTEX; KIDNEY MEDULLA; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; VALINE;

EID: 1542358797     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2004.01.002     Document Type: Article

References (27)

1. Martin P.Y., Schrier R.W. Sodium and water retention in heart failure: pathogenesis and treatment. Kidney Int Suppl. 59:1997;S57-S61.
2. Agre P., Sasaki S., Chrispeels M.J. Aquaporins: a family of water channel proteins. Am J Physiol. 265:1993;F461.
3. Kim J.K., Michel J.B., Soubrier F., Durr J., Corvol P., Schrier R.W. Arginine vasopressin gene expression in chronic cardiac failure in rats. Kidney Int. 38:1990;818-822.
4. Xu D.L., Martin P.Y., Ohara M., St John J., Pattison T., Meng X., et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest. 99:1997;1500-1505.
5. Nielsen S., Terris J., Andersen D., Ecelbarger C., Frokiaer J., Jonassen T., et al. Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc Natl Acad Sci USA. 94:1997;5450-5455.
6. The Consensus Investigators. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl J Med. 316:1987;1429-1435. The CONSENSUS Trial Study Group.
7. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. New Engl J Med. 327:1992;669-677. The SAVE Investigators.
8. Bitt B., Poole-Wilson P.A., Segal R., Martinez F.A., Dickstein K., Camm A.J., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 355:2000;1582-1587.
9. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med. 345:2001;1667-1675.
10. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 35:2000;569-582.
11. Goldstein S., Sabbah H. Ventricular remodeling and angiotensin- converting enzyme inhibitors. J Cardiovasc Pharmacol. 24:(Suppl 3):1994;S27-S31.
12. Yu C.M., Tipoe G.L., Lai K.W.H., Lau C.P. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol. 38:2001;1207-1215.
13. Kato A., Klein J.D., Zhang C., Sands J.M. Angiotensin II increases vasopressin-stimulated facilitated urea permeability in rat terminal IMCDs. Am J Physiol Renal Physiol. 279:2000;F835-F840.
14. Fishbein M.C., Maclean D., Maroko P.R. Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am J Pathol. 90:1978;57-70.
15. Jonas J.C., Sharma A., Hasenkamp W., Ilkova H., Patane G., Laybutt R., et al. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem. 274:1999;14112-14121.
16. Tang S., Leung J.C., Lam C.W., Lai F.M., Chan T.M., Lai K.N. In vitro studies of aquaporins 1 and 3 expression in cultured human proximal tubular cells: upregulation by transferrin but not albumin. Am J Kidney Dis. 38:2001;317-330.
17. Schrier R.W., Martin P.Y. Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol. 449:1998;415-426.
18. Schrier R.W., Fassett R.G. Pathogenesis of sodium and water retention in cardiac failure. Renal Fail. 20:1998;773-781.
19. Schrier R.W., Cadnapaphornchai M.A., Ohara M. Water retention and aquaporins in heart failure, liver disease and pregnancy. J Roy Soc Med. 94:2001;265-269.
20. Fujita N., Ishikawa S.E., Sasaki S., Fujisawa G., Fushimi K., Marumo F., et al. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats. Am J Physiol. 269:1995;F926-F931.
21. Marples D., Christensen S., Christensen E.I., Ottosen P.D., Nielsen S. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest. 95:1995;1838-1845.
22. Marples D., Frokiaer J., Dorup J., Knepper M.A., Nielsen S. Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest. 97:1996;1960-1968.
23. Frokiaer J., Christensen B.M., Marples D., Djurhuus J.C., Jensen U.B., Knepper M.A., et al. Downregulation of aquaporin-2 parallels changes in renal water excretion in unilateral ureteral obstruction. Am J Physiol. 273:1997;F213-F223.
24. Staahltoft D., Nielsen S., Janjua N.R., Christensen S., Skott O., Marcussen N., et al. Losartan treatment normalizes renal sodium and water handling in rats with mild congestive heart failure. Am J Physiol Renal Physiol. 282:2002;F307-F315.
25. Martin P.Y., Abraham W.T., Lieming X., Olson B.R., Oren R.M., Ohara M., et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol. 10:1999;2165-2170.
26. Christensen B.M., Marples D., Jensen U.B., Frokiaer J., Sheikh-Hamad D., Knepper M., et al. Acute effects of vasopressin V2-receptor antagonist on kidney AQP2 expression and subcellular distribution. Am J Physiol. 275:1998;F285-F297.
27. Konstam M.A., Rousseau M.F., Kronenberg M.W., Udelson J.E., Melin J., Stewart D., et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation. 86:1992;431-438. SOLVD Investigators.